TV
Travere Therapeutics, Inc.
TVTX · NASDAQ
$62.76 -3.28% (-$2.13)
1M -4.49%
Market Cap $6.02B
P/E Ratio -
Div. Yield -
ROE 55.79%
Piotroski F-Score Moderate
5/9Valuation
0 /100
Expensive EV/EBITDA 4,222.49x
P/FCF 116.86x
P/S 10.18x
Growth
100 /100
Growing Rev. growth 64.89%
Book val. growth 38.90%
EPS growth N/A
Profitability
38 /100
Moderate Gross margin 94.41%
FCF margin 8.71%
Net margin 7.35%
Quality
9 /100
Poor ROIC 6.25%
Asset turnover 0.74x
ROE 55.79%
Debt
15 /100
High Debt/Equity 25.16x
Net debt/EBITDA 323.30x
Current ratio 4.05x
Stability
23 /100
Unstable Beta 1.06x
Profitable years 0
Rev. volatility 39.40%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na TVTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Eric Dube
Employees
497
Headquarters
San Diego
Nadcházející události
29 ŘÍJ
Earnings
Upcoming earnings report